NYSE:CCChemours Stock Price, Forecast & News

Chemours' stock was trading at $10.66 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CC stock has increased by 86.5% and is now trading at $19.88.
View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Chemours.

Chemours is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Chemours.

Chemours Co (NYSE:CC) announced its quarterly earnings results on Thursday, July, 30th. The specialty chemicals company reported $0.18 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.09 by $0.09. The specialty chemicals company had revenue of $1.09 billion for the quarter, compared to analysts' expectations of $1.08 billion. Chemours had a negative net margin of 2.28% and a positive return on equity of 47.31%.
View Chemours' earnings history.

Chemours declared a quarterly dividend on Wednesday, July 29th. Stockholders of record on Monday, August 17th will be paid a dividend of $0.25 per share on Tuesday, September 15th. This represents a $1.00 annualized dividend and a yield of 5.03%. The ex-dividend date is Friday, August 14th.
View Chemours' dividend history.

11 analysts have issued 1 year price targets for Chemours' shares. Their forecasts range from $11.00 to $22.00. On average, they anticipate Chemours' share price to reach $16.60 in the next twelve months. This suggests that the stock has a possible downside of 16.5%.
View analysts' price targets for Chemours.

News headlines about CC stock have trended extremely negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chemours earned a coverage optimism score of -4.8 on InfoTrie's scale. They also gave news stories about the specialty chemicals company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Chemours.

Some companies that are related to Chemours include ASAHI KASEI COR/ADR (AHKSY), Johnson Matthey (JMPLY), Ashland Global (ASH), Huntsman (HUN), KURARAY CO LTD/ADR (KURRY), Balchem (BCPC), W. R. Grace & Co (GRA), Univar (UNVR), SHOWA DENKO KK/ADR (SHWDY), Ingevity (NGVT), GCP Applied Technologies (GCP), Innospec (IOSP), Olin (OLN), PQ Group (PQG) and Livent (LTHM).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include E I Du Pont De Nemours And Co (DD), AT&T (T), NVIDIA (NVDA), Micron Technology (MU), Pfizer (PFE), Cisco Systems (CSCO), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA) and Energy Transfer LP Unit (ET).

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours' stock is owned by a variety of retail and institutional investors. Top institutional investors include LSV Asset Management (2.51%), DNB Asset Management AS (0.53%), M&T Bank Corp (0.40%), Principal Financial Group Inc. (0.31%), Swiss National Bank (0.22%) and Brightline Capital Management LLC (0.20%). Company insiders that own Chemours stock include Amy Trojanowski, Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher.
View institutional ownership trends for Chemours.

CC stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, DNB Asset Management AS, SG Americas Securities LLC, LSV Asset Management, Raymond James Financial Services Advisors Inc., New York State Common Retirement Fund, Dupont Capital Management Corp, and M&T Bank Corp.
View insider buying and selling activity for Chemours.

CC stock was purchased by a variety of institutional investors in the last quarter, including Brightline Capital Management LLC, Trexquant Investment LP, Swiss National Bank, First Quadrant L P CA, Raymond James & Associates, State of Michigan Retirement System, Russell Investments Group Ltd., and DAVENPORT & Co LLC. Company insiders that have bought Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown, and Susan M Kelliher.
View insider buying and selling activity for Chemours.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CC stock can currently be purchased for approximately $19.88.

Chemours has a market capitalization of $3.27 billion and generates $5.53 billion in revenue each year. The specialty chemicals company earns $-52,000,000.00 in net income (profit) each year or $2.51 on an earnings per share basis. Chemours employs 7,000 workers across the globe.

The official website for Chemours is www.chemours.com.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]